



1623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: L. J. Stuyver *et al.*
Serial No.: 10/045,292
Filed: October 18, 2001
Title: Modified Nucleosides for the Treatment of Viral Infections
and Abnormal Cellular Proliferation

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 28, 2003


Transmittal of Supplemental Information Disclosure Statement

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Additionally, Applicants enclose a copy of the International Search Report corresponding to PCT/US01/46113 as well as copies of the cited references. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.


Respectfully submitted,


Hoang M. Vo
Reg. No. 47,158

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-2452 (Telephone)
404-572-5145 (Facsimile)

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as Express Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Hoang M. Vo
Reg. No. 47,158

Date: October 28, 2003

OCT 31 2003
U.S. PATENT & TRADEMARK OFFICE

Please use a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/045,292
				Filing Date	18-Oct-2001
				First Named Inventor	Stuyver, Lieven J. <i>et al.</i>
				Group Art Unit	N/A
Sheet	1	of	1	Attorney Docket Number	PHA 1020 US

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AA	WO	9818324		Loeb, L. A.; Mullins, J.I; Univ. Washington	07.05.98		
	AB	JP	61-130299		Daikin Kogyo	18.06.86		
	AC	WO	01/60315A		BioChem Pharma	23.08.01		
	AD	WO	02/18404A		Hoffmann La Roche	07.03.02		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	AE	LOCKSHIN, Arnold et al; "Selective cytotoxicity of 5-hydroxyuridine for human colon adenocarcinoma cells", Cancer Treatment Reports (July/August 1985), 69 (7-8), 845-9			
	AF	DOLLINGER, Malin R. et al: "Analogues of 1-D-arabinofuranosylcytosine. Studies on mechanisms of action in Burkitt's cell culture and mouse leukemia, and in vitro deamination studies", Biochemical Pharmacology (1967), 16(4), 689-706			
	AG	HOSHINO, Jiro, et al: "Suppression of nuclear ADP-ribosyltransferase activity in Ehrlich ascites tumor cells by 5-azacytidine and its analogs", Biochemical and Biophysical Research Communications (Jan. 1987), 142(2), 468-7			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.